Re: Investment Analysts’ Ratings Reiterations for July, 25th

Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Have a great Sunday, especially those of you like me that are celebrating Orthodox Easter ... As well as those of you who are also like me and mourning another Maple Leafs Game 7 exit ... Ugggh!

Sincerely,

George et al

Reply New Message

Prev Message Back To Forum Threaded View Next Message

brentie98

Rank: President [?]

Points: 5496 [?]

Votes: 21 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Investment Analysts’ Ratings Reiterations for July, 25th

in response to

Re: Investment Analysts’ Ratings Reiterations for July, 25th

typecheck

posted on Jul 25, 2012 06:32PM

Good question,Typecheck.Here's more from Zacks.

MannKind (NASDAQ: MNKD)‘s stock had its “neutral” rating restated by Zacks in a report issued on Wednesday. They currently have a $2.50 targetprice on the stock.

Zacks‘ analyst wrote, “MannKind’s first quarter 2012 net loss of $0.27 per share was narrower than the year-ago loss of $0.34, mainly due to lower expenses. We expect investor focus to remain on the fate of diabetes candidate, Afrezza, which received a second CRL from the FDA in January 2011. The company is currently conducting two additional trials, scheduled to complete early next year. Positive results would allow MannKind to file the NDA by the first half of 2013. However, we remain concerned about the slower-than-expected enrolment process. Meanwhile, we are positive on MannKind’s agreement with Tolero which not only provides the company with funds but also allows the company to share the risks associated with the development of pipeline candidates.”

MannKind traded up 2.62% on Wednesday, hitting $2.55. MannKind has a 1-year low of $1.57 and a 1-year high of $3.95. The company’s marketcap is $405.0 million.

MannKind last released its earnings data on Wednesday, May 9th. The company reported ($0.27) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.04. Analysts expect that MannKind will post $-0.97 EPS for the current fiscal year.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.